Press release
Investigation announced for Investors in shares of Reata Pharmaceuticals, Inc. (NASDAQ: RETA)
An investigation for investors in Reata Pharmaceuticals, Inc. (NASDAQ: RETA) shares over potential securities laws violations.
Investors who purchased shares of Reata Pharmaceuticals, Inc. (NASDAQ: RETA), have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm focuses on whether a series of statements by Reata Pharmaceuticals, Inc. regarding its business, its prospects and its operations were materially false and misleading at the time they were made.
Plano, TX based Reata Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops novel therapeutics for patients with serious or life-threatening diseases by targeting molecular pathways that regulate cellular metabolism and inflammation. Reata Pharmaceuticals, Inc. reported that its annual Total Revenue declined from $26.51 million in 2019 to $9.01 million in 2020, and that its Net Loss declined from $290.17 million in 2019 to $247.75 million in 2020.
On December 6, 2021, the FDA released a briefing document regarding Reata Pharmaceuticals, Inc’s chronic kidney disease drug candidate, bardoxolone methyl. Therein, the FDA stated that the data submitted by Reata Pharmaceuticals, Inc did not “demonstrate that bardoxolone is effective in slowing the loss of kidney function in patients with [Alport syndrome].”
Shares of Reata Pharmaceuticals, Inc. (NASDAQ: RETA) declined from $95.34 per share on December 1, 2021, to $27.50 per share on December 10, 2021.
Those who purchased shares of Reata Pharmaceuticals, Inc. (NASDAQ: RETA) have certain options and should contact the Shareholders Foundation.
Contact:
Michael Daniels
Shareholders Foundation, Inc.
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108
Tel: +1-(858)-779-1554
E-Mail: mail@shareholdersfoundation.com
About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, and an investor advocacy group, which does research related to shareholder issues and informs investors of securities lawsuits, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Investigation announced for Investors in shares of Reata Pharmaceuticals, Inc. (NASDAQ: RETA) here
News-ID: 2496511 • Views: …
More Releases from Shareholders Foundation
Lawsuit filed for certain Investors who lost money with shares of Global Cord Bl …
An investor, who purchased shares of Global Cord Blood Corporation (OTC: CORBF), filed a lawsuit over alleged violations of Federal Securities Laws by Global Cord Blood Corporation in connection with certain allegedly false and misleading statements.
Investors who purchased shares of Global Cord Blood Corporation (OTC: CORBF) have certain options and for certain investors are short and strict deadlines running. Deadline: June 24, 2024. OTC: CORBF investors should contact the Shareholders…
Lawsuit filed for Investors who lost money with shares of Autodesk, Inc. (NASDAQ …
An investor, who purchased shares of Autodesk, Inc. (NASDAQ: ADSK), filed a lawsuit over alleged violations of Federal Securities Laws by Autodesk, Inc. in connection with certain allegedly false and misleading statements.
Investors who purchased shares of Autodesk, Inc. (NASDAQ: ADSK) have certain options and for certain investors are short and strict deadlines running. Deadline: June 24, 2024. NASDAQ: ADSK investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858)…
Investors who lost money with shares of AST SpaceMobile, Inc. (NASDAQ: ASTS) sho …
An investor, who purchased shares of AST SpaceMobile, Inc. (NASDAQ: ASTS), filed a lawsuit over alleged violations of Federal Securities Laws by AST SpaceMobile, Inc. in connection with certain allegedly false and misleading statements.
Investors who purchased shares of AST SpaceMobile, Inc. (NASDAQ: ASTS) have certain options and for certain investors are short and strict deadlines running. Deadline: June 17, 2024. NASDAQ: ASTS investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com…
Lawsuit filed for Investors who lost money with shares of Sharecare, Inc. (NASDA …
An investor, who purchased shares of Sharecare, Inc. (NASDAQ: SHCR), filed a lawsuit over alleged violations of Federal Securities Laws by Sharecare, Inc.
Investors who purchased shares of Sharecare, Inc. (NASDAQ: SHCR) have certain options and for certain investors are short and strict deadlines running. Deadline: June 18, 2024. NASDAQ: SHCR investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
Atlanta, GA based Sharecare, Inc. operates as…
More Releases for Reata
Investigation for Long-Term Investors in shares of Reata Pharmaceuticals, Inc. ( …
An investigation was announced concerning potential breaches of fiduciary duties by certain directors of Reata Pharmaceuticals, Inc.
Investors who are current long term investors in Reata Pharmaceuticals, Inc. (NASDAQ: RETA) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm for current long term investors in NASDAQ: RETA stocks follows a lawsuit filed against Reata Pharmaceuticals, Inc.…
Lawsuit filed for Investors in Reata Pharmaceuticals, Inc. (NASDAQ: RETA) shares
An investor, who purchased shares of Reata Pharmaceuticals, Inc. (NASDAQ: RETA), filed a lawsuit iover alleged violations of Federal Securities Laws by Reata Pharmaceuticals, Inc.
Investors who purchased shares of Reata Pharmaceuticals, Inc. (NASDAQ: RETA) have certain options and for certain investors are short and strict deadlines running. Deadline: December 14, 2020. NASDAQ: RETA investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
On August 10, 2020,…
Investigation announced for Investors in Reata Pharmaceuticals, Inc. (NASDAQ: RE …
An investigation was announced over potential breaches of fiduciary duties by certain officers and directors at Reata Pharmaceuticals, Inc.
Investors who purchased shares of Reata Pharmaceuticals, Inc. (NASDAQ: RETA) have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm concerns whether certain Reata Pharmaceuticals, Inc. directors breached their fiduciary duties and caused damage to the company and its shareholders.
Plano,…
Investigation announced for Investors in shares of Reata Pharmaceuticals, Inc. ( …
An investigation was announced concerning potential securities laws violations by Reata Pharmaceuticals, Inc. in connection with certain financial statements.
Investors who purchased shares of Reata Pharmaceuticals, Inc. (NASDAQ: RETA), have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm focuses on whether a series of statements by Reata Pharmaceuticals, Inc. regarding its business, its prospects and its operations were…
Ataxia Therapeutics Pipeline Analysis 2018 | Reata Pharmaceuticals, Inc., Voyage …
Ataxia is a type of movement disorder characterized by lack of muscle control or coordination of voluntary movements. Some of the symptoms observed in the patients with ataxia are poor coordination, change in speech, difficulty in swallowing, and unsteady walk.
Download the sample report @ https://www.pharmaproff.com/request-sample/1078
The disease causes include head injury; stroke; autoimmune diseases, such as sarcoidosis and multiple sclerosis; paraneoplastic syndromes; and viral infections. The disease is also found in…
Diabetic Nephropathy market 2020 | Pfizer, Inc., Merck & Co., Inc., Sanofi, Reat …
Diabetic nephropathy is known as the most significant impediment occurring in the kidney glomerulus which render the patient morbid or even worse in majority of the cases. Characterized by macroalbuminuria, diabetic nephropathy is diagnosed when more than 300 milligrams of albumin are present in the urine in a day. The global market for diabetic nephropathy was valued at US$ 2,262.2 million in 2014. Registering a steady CAGR of 5.6%, the…
